Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics

被引:154
作者
Fattet, Sarah [2 ,3 ]
Haberler, Christine [2 ,4 ]
Legoix, Patricia [5 ]
Varlet, Pascale [6 ]
Lellouch-Tubiana, Arielle [7 ,8 ]
Lair, Severine [9 ,10 ]
Manie, Elodie [2 ]
Raquin, Marie-Anne [11 ]
Bours, Danielle
Carpentier, Sabrina [9 ,10 ]
Barillot, Emmanuel [9 ,10 ]
Grill, Jacques [11 ]
Doz, Francois [7 ,12 ]
Puget, Stephanie [8 ]
Janoueix-Lerosey, Isabelle [2 ]
Delattre, Olivier [1 ,2 ]
机构
[1] Inst Curie, INSERM, Ctr Rech, U830, F-75248 Paris 05, France
[2] INSERM, Lab Genet & Biol Canc, U830, F-75248 Paris 05, France
[3] CHU Vaudois, CH-1011 Lausanne, Switzerland
[4] Med Univ Vienna, Inst Neurol, A-1097 Vienna, Austria
[5] Inst Curie, Dept Transfert, F-75248 Paris 05, France
[6] Ctr Hosp St Anne, Neuropathol Lab, F-75014 Paris, France
[7] Univ Paris 05, Fac Med, F-75006 Paris, France
[8] Hop Necker Enfants Malad, F-75015 Paris, France
[9] INSERM, U900, F-75248 Paris 05, France
[10] Ecole Mines ParisTech, F-77300 Fontainebleau, France
[11] Inst Gustave Roussy, F-94805 Villejuif, France
[12] Inst Curie, F-75005 Paris, France
基金
奥地利科学基金会;
关键词
medulloblastoma; CTNNB1; mutation; beta-catenin; chromosome; 6; deletion; array CGH; expression profile; immunocytochemistry; survival; neoplasia; STANDARD-RISK MEDULLOBLASTOMA; CHILDHOOD MEDULLOBLASTOMA; PROGNOSTIC-FACTORS; TUMOR; CHEMOTHERAPY; CHILDREN; PATHWAY; STRATIFICATION; RADIOTHERAPY; PREDICTS;
D O I
10.1002/path.2514
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medulloblastoma is the most frequent malignant paediatric brain tumour. The activation of the Wnt/beta-catenin pathway occurs in 10-15% of medulloblastomas and has been recently described as a marker for favourable patient outcome. We report a series of 72 paediatric medulloblastomas evaluated for beta-catenin protein expression, CTNNB1 mutations, and comparative genomic hybridization. Gene expression profiles were also available in a subset of 40 cases. Immunostaining of beta-catenin showed extensive nuclear staining (>50% of the tumour cells) in six cases and focal nuclear staining (<10 % of cells) in three cases. The other cases either exhibited a signal strictly limited to the cytoplasm (58 cases) or were negative (five cases). CTNNB1 mutations were detected in all beta-catenin extensively nucleopositive cases. The expression profiles of these cases documented strong activation of the Wnt/beta-catenin pathway. Remarkably, five out of these six tumours showed a complete loss of chromosome 6. In contrast, cases with focal nuclear beta-catenin staining, as well as tumours with negative or cytoplasmic staining, never demonstrated CTNNB1 mutation, Wnt/beta-catenin pathway activation or chromosome 6 loss. Patients with extensive nuclear staining were significantly older at diagnosis and were in continuous complete remission after a mean follow-up of 75.7 months (range 27.5-121.2 months) from diagnosis. All three patients with focal nuclear staining of beta-catenin died within 36 months from diagnosis. Altogether, these data confirm and extend previous observations that CTNNB1-mutated tumours represent a distinct molecular subgroup of medulloblastomas with favourable outcome, indicating that therapy de-escalation should be considered. International consensus on the definition criteria of this distinct medulloblastoma subgroup should be achieved. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:86 / 94
页数:9
相关论文
共 35 条
[1]   Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy:: Results of the French M-SFOP 98 protocol [J].
Carrie, C ;
Muracciole, X ;
Gomez, F ;
Habrand, JL ;
Benhassel, M ;
Mege, M ;
Mahé, M ;
Quetin, P ;
Maire, JP ;
Soum, F ;
Baron, MH ;
Clavere, P ;
Chapet, S ;
Gaci, Z ;
Kolodie, H ;
Maingon, P ;
Vie, B ;
Bernier, V ;
Alapetite, C ;
Hoffstetter, S ;
Grill, J ;
Lafay, F .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03) :711-716
[2]   Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis [J].
Clifford, Steven C. ;
Lusher, Meryl E. ;
Lindsey, Janet C. ;
Langdon, Jacqueline A. ;
Gilbertson, Richard J. ;
Straughton, Debbie ;
Ellison, David W. .
CELL CYCLE, 2006, 5 (22) :2666-2670
[3]   Histopathologic grading of medulloblastomas - A pediatric oncology group study [J].
Eberhart, CG ;
Kepner, JL ;
Goldthwaite, PT ;
Kun, LE ;
Duffner, PK ;
Friedman, HS ;
Strother, DR ;
Burger, PC .
CANCER, 2002, 94 (02) :552-560
[4]   Nuclear localization and mutation of β-catenin in medulloblastomas [J].
Eberhart, CG ;
Tihan, T ;
Burger, PC .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (04) :333-337
[5]   β-catenin status predicts a favorable outcome in childhood medulloblastoma:: The United Kingdom Children's Cancer Study Group Brain Tumour Committee [J].
Ellison, DW ;
Onilude, OE ;
Lindsey, JC ;
Lusher, ME ;
Weston, CL ;
Taylor, RE ;
Pearson, AD ;
Clifford, SC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7951-7957
[6]   Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial [J].
Gajjar, Amar ;
Chintagumpala, Murali ;
Ashley, David ;
Kellie, Stewart ;
Kun, Larry E. ;
Merchant, Thomas E. ;
Woo, Shaio ;
Wheeler, Greg ;
Ahern, Valerie ;
Krasin, Matthew J. ;
Fouladi, Maryam ;
Broniscer, Alberto ;
Krance, Robert ;
Hale, Gregory A. ;
Stewart, Clinton F. ;
Dauser, Robert ;
Sanford, Robert A. ;
Fuller, Christine ;
Lau, Ching ;
Boyett, James M. ;
Wallace, Dana ;
Gilbertson, Richard J. .
LANCET ONCOLOGY, 2006, 7 (10) :813-820
[7]   Stratification of medulloblastoma on the basis of histopathological grading [J].
Giangaspero, Felice ;
Wellek, Stefan ;
Masuoka, Jun ;
Gessi, Marco ;
Kleihues, Paul ;
Ohgaki, Hiroko .
ACTA NEUROPATHOLOGICA, 2006, 112 (01) :5-12
[8]   Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children [J].
Grill, J ;
Sainte-Rose, C ;
Jouvet, A ;
Gentet, JC ;
Lejars, O ;
Frappaz, D ;
Doz, F ;
Rialland, X ;
Pichon, F ;
Bertozzi, AI ;
Chastagner, P ;
Couanet, D ;
Habrand, JL ;
Raquin, MA ;
Le Deley, MC ;
Kalifa, C .
LANCET ONCOLOGY, 2005, 6 (08) :573-580
[9]   Histopathological prognostic factors in medulloblastoma: High expression of survivin is related to unfavourable outcome [J].
Haberler, C. ;
Slavc, I. ;
Czech, T. ;
Gelpi, E. ;
Heinzl, H. ;
Budka, H. ;
Urban, C. ;
Scarpatetti, M. ;
Ebetsberger-Dachs, G. ;
Schindler, C. ;
Jones, N. ;
Klein-Franke, A. ;
Maier, H. ;
Jauk, B. ;
Kiefer, A. ;
Hainfellner, J. A. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (17) :2996-3003
[10]   Two types of chromosome 1p losses with opposite significance in gliomas [J].
Idbaih, A ;
Marie, Y ;
Pierron, G ;
Brennetot, C ;
Khê, HX ;
Kujas, M ;
Mokhtari, K ;
Sanson, M ;
Lejeune, J ;
Aurias, A ;
Delattre, O ;
Delattre, JY .
ANNALS OF NEUROLOGY, 2005, 58 (03) :483-487